Mirum Pharmaceuticals (MIRM) Non-Current Assets (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Non-Current Assets of $321.5 million for Q1 2026, up 15.05% year-over-year from $279.4 million in Q1 2025, and up 9.67% quarter-over-quarter from $293.1 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Non-Current Assets (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $321.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 15.05% year-over-year to $321.5 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 0.88% YoY), while the FY2025 annual figure was $293.1 million, up 5.45% from the prior year.
- Non-Current Assets for Q1 2026 stood at $321.5 million, up from $293.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $321.5 million in Q1 2026, with the low at $60.1 million in Q2 2023.
- The 5-year median for Non-Current Assets is $262.1 million (2023), against an average of $227.2 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 2639.19% in 2022, then sank 59.95% in 2023.
- Mirum Pharmaceuticals' Non-Current Assets stood at $162.7 million in 2022, then jumped by 59.26% to $259.1 million in 2023, then climbed by 7.29% to $278.0 million in 2024, then climbed by 5.45% to $293.1 million in 2025, then climbed by 9.67% to $321.5 million in 2026.
- Business Quant data shows MIRM's Non-Current Assets at $321.5 million in Q1 2026, $293.1 million in Q4 2025, and $254.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 408.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 408.67 Mn |
| Mar 31, 2026 | 321.48 Mn |
| Dec 31, 2025 | 293.13 Mn |
| Sep 30, 2025 | 254.54 Mn |
| Jun 30, 2025 | 272.43 Mn |
| Mar 31, 2025 | 279.43 Mn |
| Dec 31, 2024 | 277.97 Mn |
| Sep 30, 2024 | 281.27 Mn |
| Jun 30, 2024 | 292.93 Mn |
| Mar 31, 2024 | 262.50 Mn |
| Dec 31, 2023 | 259.08 Mn |
| Sep 30, 2023 | 262.06 Mn |
| Jun 30, 2023 | 60.07 Mn |
| Mar 31, 2023 | 161.20 Mn |
| Dec 31, 2022 | 162.68 Mn |
| Sep 30, 2022 | 148.79 Mn |
| Jun 30, 2022 | 149.99 Mn |
| Mar 31, 2022 | 122.88 Mn |
| Dec 31, 2021 | 128.06 Mn |
| Sep 30, 2021 | 38.36 Mn |